keyword
transplant
infect
critic
care
immunosuppress
opportunist
infect
microbiolog
diagnosi
transplant
patient
repres
heterogen
rapidli
grow
patient
group
requir
high
index
suspicion
infect
infect
major
posttranspl
caus
morbid
mortal
new
threat
continu
emerg
individu
assess
net
state
immunosuppress
infect
risk
import
aggress
pursuit
earli
microbiolog
diagnosi
crucial
invas
procedur
use
necessari
set
lifethreaten
infect
reduct
cessat
immunosuppress
therapi
whenev
possibl
import
adjunct
therapi
crit
care
clin
http
dx
transplant
recipi
constitut
increasingli
divers
complex
patient
cohort
compris
heterogen
patient
group
undergo
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
pancreat
islet
cell
transplant
also
includ
emerg
group
individu
undergo
vascular
composit
allotransplant
limb
transplant
infect
remain
major
caus
morbid
mortal
transplant
recipi
exampl
approxim
mortal
follow
allogen
hsct
attribut
infect
sot
immunosuppress
prescrib
indefinit
transplant
physician
patient
perpetu
negoti
delic
balanc
risk
graft
reject
infect
advanc
techniqu
modern
immunosuppress
improv
graft
surviv
continu
unveil
new
infect
challeng
disclosur
humar
receiv
grant
support
roch
consult
fee
astella
transplant
infecti
diseas
alberta
transplant
institut
univers
alberta
katz
center
health
research
ave
edmonton
alberta
canada
patient
pharmacolog
immunosuppress
evolv
dramat
recent
year
plethora
agent
avail
physician
use
box
specif
agent
vari
greatli
mode
intens
durat
immunosuppress
ad
yet
anoth
layer
complex
manag
prevent
infecti
morbid
mortal
transplant
recipi
risk
infect
transplant
recipi
dynam
process
numer
influenc
factor
must
consid
evalu
patient
box
net
state
immunosuppress
central
concept
transplant
medicin
repres
key
determin
infecti
risk
net
state
measur
individu
uniqu
suscept
infect
incorpor
assess
sever
import
contribut
factor
time
transplant
also
key
import
fig
tabl
directli
influenc
potenti
pathogen
individu
patient
risk
follow
period
intensif
immunosuppress
eg
due
graft
reject
flare
graftversushost
diseas
gvhd
patient
infect
risk
adjust
reflect
earlier
time
point
transplant
absenc
chronic
gvhd
requir
ongo
immunosuppress
hsct
recipi
immun
restitut
gener
consid
complet
year
stem
cell
transplant
author
learn
object
review
signific
posttranspl
infect
necessit
critic
care
support
eas
descript
discuss
divid
infect
present
earli
transplant
occur
later
transplant
detail
discuss
specif
pathogen
follow
earli
infect
classifi
sot
encount
transplant
procedur
week
transplant
hsct
infect
occur
preengraft
phase
infecti
entiti
uniqu
transplant
recipi
emerg
pathogen
import
emphas
understand
mani
frequent
observ
infect
dealt
articl
equal
applic
cohort
patient
transplant
recipi
frequent
user
critic
care
servic
intensivist
form
integr
part
posttranspl
care
pathway
follow
sot
mani
patient
routin
receiv
initi
period
postop
care
critic
care
set
later
posttranspl
period
patient
requir
critic
care
support
manag
infect
manifest
sever
septic
shock
set
sever
compromis
vital
organ
function
eg
pneumonia
diseas
affect
central
nervou
system
cn
recognit
infect
transplant
recipi
notori
difficult
maintain
high
index
suspicion
paramount
import
present
infect
frequent
alter
due
impair
innat
adapt
immun
respons
absenc
fever
preclud
possibl
seriou
infect
local
sign
may
absent
identifi
late
diseas
process
multidisciplinari
approach
essenti
achiev
optim
outcom
patient
approach
involv
transplant
physician
transplant
surgeon
critic
care
clinician
clinic
pharmacist
alli
health
specialist
work
togeth
core
success
diagnosi
manag
thorough
assess
infecti
risk
detail
histori
physic
examin
inclus
cutan
ophthalmolog
examin
frequent
provid
subtl
vital
diagnost
clue
microbiolog
diagnosi
crucial
patient
group
context
extens
differenti
diagnos
valu
earli
specif
diagnost
use
invas
procedur
necessari
bronchoscopi
tissu
biopsi
aspir
collect
obtain
specimen
overemphas
box
transplant
serolog
techniqu
limit
use
transplant
recipi
may
mount
time
serolog
respons
antigen
detect
molecular
nucleic
acid
detect
assay
prefer
adopt
newer
microbiolog
techniqu
pathogen
identif
carri
potenti
improv
abil
achiev
definit
diagnosi
greatli
enabl
prompt
commenc
specif
antimicrobi
detail
radiolog
examin
use
comput
tomographi
ct
scan
magnet
reson
imag
mri
allow
earli
identif
occult
site
infect
howev
instanc
follow
collect
initi
specimen
cultur
immedi
institut
empir
broad
antimicrobi
coverag
target
like
pathogen
imper
noninfecti
entiti
also
precipit
ill
requir
critic
care
support
transplant
recipi
may
mimic
infect
alway
born
mind
transplant
recipi
suscept
episod
graft
reject
gvhd
flare
even
recurr
primari
diseas
addit
advers
effect
aris
drug
toxic
drugdrug
interact
resembl
infecti
entiti
may
observ
eg
sirolimusinduc
pneumon
effect
manag
infect
transplant
often
necessit
reduct
immunosuppress
possibl
manag
alter
net
state
immunosuppress
favor
enabl
robust
host
immun
respons
adjuv
immunotherapi
use
immunoglobulin
use
certain
infect
addit
therapeut
concern
relat
drug
interact
antimicrobi
immunosuppress
drug
appropri
dose
deliveri
critic
ill
patient
vital
organ
dysfunct
surgic
intervent
may
requir
aid
diagnosi
effect
definit
manag
earli
period
posttransplant
bacteri
infect
predomin
frequent
issu
aris
relat
common
nosocomi
infecti
complic
bloodstream
infect
bsi
catheterassoci
bsi
health
careventilatorassoci
pneumonia
urinari
tract
infect
uti
surgic
site
infect
clostridium
difficileassoci
diarrhea
risk
infect
relat
technic
difficulti
transplant
procedur
well
pretranspl
statu
recipi
usual
nosocomi
pathogen
prevail
staphylococcu
aureu
coagulaseneg
staphylococci
enterococci
enterobacteriacea
pseudomona
aeruginosa
consequ
signific
health
care
exposur
antimicrobialresist
pathogen
methicillinresist
aureu
mrsa
vancomycinresist
enterococcu
vre
extend
spectrum
blactamas
esbl
produc
gramneg
organ
encount
increas
frequenc
transplant
recipi
addit
antimicrobi
prophylaxi
prior
treatment
episod
markedli
alter
individu
commens
flora
thu
heighten
awar
organ
less
frequent
encount
requir
certain
circumst
empir
therapi
take
organ
consider
eg
stenotrophomona
maltophila
acinetobact
baumannii
complex
given
mortal
associ
delay
therapi
candida
infect
candidemia
frequent
encount
critic
care
set
preval
nonalbican
candida
speci
continu
increas
transplant
recipi
shift
promot
use
antifung
prophylaxi
follow
hsct
solidorgan
transplant
transplant
recipi
increas
incid
infect
c
difficil
experi
sever
diseas
highest
incid
first
month
transplant
relaps
diseas
common
prolong
cours
therapi
often
requir
specif
sot
risk
donorderiv
infect
infect
origin
within
oper
field
donorderiv
infect
broad
rang
potenti
infect
pathogen
transmit
organ
transplant
infect
pathogen
includ
follow
unexplain
fever
earli
transplant
alter
mental
statu
sign
unexplain
multiorgan
failur
despit
thorough
investig
rais
possibl
donorderiv
infect
open
commun
relev
organ
procur
organ
vital
situat
aris
oper
field
infect
earli
posttranspl
residu
fluid
collect
hematoma
conjunct
devit
tissu
leak
anastomos
provid
ideal
condit
establish
deepseat
infect
vascular
complic
thrombosi
vessel
may
also
occur
lead
graft
ischemia
dysfunct
necrosi
earli
radiolog
diagnosi
intervent
critic
approach
diagnosi
manag
often
necessit
surgic
intervent
microbiolog
diagnosi
perform
effect
debrid
lung
transplant
recipi
experi
highest
frequenc
infect
among
sot
recipi
infect
incid
doubl
heart
transplant
recipi
contributori
factor
includ
donor
lung
colon
extend
period
intub
disrupt
lymphat
drainag
reduc
cough
reflex
ciliari
function
intens
immunosuppress
particular
attent
paid
bronchial
anastomos
suscept
ischemia
breakdown
infect
mediastin
pleuralbas
diseas
preval
cardiothorac
transplant
recipi
earli
imag
ct
indic
posttranspl
infect
clinic
concern
exist
occasion
cultureneg
surgic
site
infect
may
attribut
unusu
pathogen
mycoplasma
homini
cystic
fibrosi
patient
undergo
lung
transplant
deserv
particular
mention
often
come
transplant
colon
resist
fastidi
organ
colon
multidrugresist
pseudomona
colon
burkholderia
spp
patient
requir
individu
antimicrobi
prophylact
regimen
breakthrough
infect
still
occur
breakthrough
infect
manifest
sepsi
empyema
lung
abscess
central
venou
catheterassoci
bsi
earli
late
transplant
close
surveil
earli
aggress
therapi
essenti
antimicrobi
therapi
optim
base
suscept
test
sourc
control
entail
cathet
remov
drainag
site
infect
pursu
critic
care
set
earli
posttransplant
nosocomi
infect
prevail
gramneg
bacilli
enterococci
anaerob
organ
repres
predomin
pathogen
infect
relat
technic
complic
common
infect
may
due
vascular
nonvascular
anastomot
problem
thorough
understand
transplant
organ
anatomi
import
exampl
liver
transplant
recipi
biliari
anastomosi
may
leak
strictur
biliari
leak
biloma
repres
common
site
initi
infect
thrombosi
hepat
arteri
uncommon
may
lead
devast
complic
includ
hepat
abscess
necrosi
sepsi
earli
imag
diagnosi
essenti
set
liver
pancrea
intestin
recipi
particular
risk
fungal
infect
often
caus
candida
speci
close
surveil
requir
antifung
prophylaxi
recommend
patient
high
risk
intestin
recipi
reoper
retransplant
renal
failur
massiv
transfus
candida
colon
hsct
recipi
preengraft
phase
hsct
recipi
commonli
requir
critic
care
support
due
sepsi
pneumonia
sever
mucos
predispos
establish
bsi
skin
oral
gastrointestin
gi
tract
flora
catheterassoci
bsi
also
common
spectrum
bsi
pathogen
alter
time
follow
introduct
fluroquinolon
prophylaxi
incid
gnb
infect
declin
replac
increas
incid
gramposit
organ
spectrum
reflect
prevail
organ
present
within
institut
common
rise
incid
drugresist
organ
carri
increas
risk
mortal
eg
vre
esblproduc
enterobacteriacea
akin
sot
recipi
due
consider
given
possibl
unusu
bacteri
pathogen
candida
bsi
also
increasingli
due
nonalbican
speci
reflect
use
antifung
prophylaxi
candidemia
transplant
recipi
prompt
search
endorgan
site
infect
endocard
endophthalm
renal
abscess
hepatosplen
candidiasi
depend
clinic
set
sever
pneumonia
occur
preengraft
precipit
requir
critic
care
support
nosocomi
organ
respiratori
virus
caus
pneumonia
set
howev
patient
also
particularli
suscept
invas
fungal
infect
ifi
prolong
period
neutropenia
prehsct
contribut
substanti
increas
risk
ifi
earli
posthsct
aspergillu
common
pathogen
encount
overal
incid
allogen
hsct
recipi
mold
name
fusarium
zygomycet
scedosporium
spp
emerg
import
caus
ifi
hsct
recipi
manifest
pulmonari
andor
dissemin
extrapulmonari
diseas
see
detail
discuss
later
divers
approach
requir
manag
pneumonia
appropri
due
bacteri
viral
fungal
pathogen
set
emphas
import
earli
microbiolog
diagnosi
use
invas
procedur
necessari
typhliti
occur
approxim
patient
hematolog
malign
mucos
injuri
profound
neutropenia
allow
secondari
bowel
wall
infect
transmur
inflamm
cecum
often
involv
patient
present
right
lower
quadrant
pain
periton
sign
progress
septicemia
andor
bowel
perfor
occur
typhliti
clinic
diagnosi
supplement
ct
confirm
establish
extent
diseas
presenc
perfor
conserv
manag
mainstay
therapi
bowel
rest
total
parenter
nutrit
broad
spectrum
antimicrobi
cover
gut
flora
ie
gramposit
gramneg
anaerob
organ
fungi
await
neutrophil
recoveri
surgeri
recommend
case
complic
conserv
manag
fail
late
post
transplant
infect
observ
earli
posttranspl
period
continu
encount
opportunist
pathogen
communityacquir
infect
tend
domin
intens
ongo
immunosuppress
dictat
breadth
pathogen
individu
suscept
maintain
relev
critic
care
clinician
common
emerg
infect
syndrom
uniqu
transplant
recipi
discuss
approach
diagnosi
initi
manag
review
common
commun
infect
requir
critic
care
support
invas
pneumococc
staphylococc
diseas
urosepsi
meningococc
diseas
influenza
review
elsewher
transplant
recipi
present
advanc
stage
ill
manag
broadli
keep
immunocompet
individu
decis
adjust
immunosuppress
use
adjunct
immunoglobulin
therapi
base
patient
individu
clinic
circumst
pulmonari
infect
common
form
document
invas
infect
observ
transplant
recipi
frequent
caus
suffici
compromis
respiratori
function
requir
critic
care
support
differenti
diagnosi
transplant
recipi
broad
box
definit
diagnosi
crucial
effect
therapi
resolut
chest
radiograph
may
often
underestim
true
extent
diseas
ct
thorax
provid
inform
regard
extent
pattern
pulmonari
involv
presenc
cavit
nodular
infiltr
routin
diagnost
evalu
blood
cultur
remain
import
specif
test
opportunist
bronchoalveolar
lavag
bal
yield
repres
specimen
adequ
qualiti
reliabl
sputum
collect
perform
bronchoscopi
bal
consid
earli
specimen
process
potenti
bacteri
mycobacteri
fungal
viral
pathogen
see
specif
pathogen
clinician
also
maintain
low
threshold
perform
biopsi
involv
lung
tissu
histolog
cultur
infect
cn
transplant
recipi
vari
indol
present
chronic
lowgrad
headach
fulmin
meningoencephalit
present
requir
admiss
critic
care
cn
may
site
infect
isol
intracerebr
abscess
may
involv
part
dissemin
infecti
process
transplant
recipi
differenti
diagnos
present
divers
cover
spectrum
common
commun
acquir
opportunist
pathogen
box
bacteri
mri
neuroimag
modal
choic
provid
better
resolut
brain
parenchyma
improv
diagnost
specif
lumbar
punctur
perform
safe
cerebrospin
fluid
csf
process
specif
pathogen
test
eg
viral
pcr
cryptococc
antigen
see
specif
pathogen
occasion
sever
enterocol
may
requir
admiss
critic
care
due
cardiovascular
compromis
consequ
perforationbleed
transplant
recipi
predomin
infecti
etiolog
consid
c
difficil
cmv
ebv
posttranspl
lymphoprolif
disord
ptld
noroviru
rotaviru
caus
protract
diarrheal
ill
cryptosporidium
isospora
giardia
lamblia
strongyloid
stercorali
hyperinfect
syndrom
specif
diagnost
test
includ
stool
specimen
cultur
ovaparasit
examin
c
difficil
toxin
enter
viru
pcr
stool
sampl
perform
avail
often
improv
sensit
compar
electron
microscopi
colonoscopi
tissu
biopsi
may
requir
diagnos
cmv
definit
set
cmv
coliti
cmv
may
detect
plasma
pcr
follow
discuss
select
pathogen
particularli
common
caus
lifethreaten
sever
ill
transplant
recipi
cmv
one
preval
opportunist
pathogen
posttranspl
develop
sensit
diagnost
test
advent
prophylacticpreempt
strategi
cmv
reactiv
rate
observ
signific
attribut
morbid
mortal
current
widespread
use
prophylaxi
preemptiv
prevent
strategi
mortal
due
cmv
declin
substanti
despit
advanc
cmv
remain
import
pathogen
transplant
seroneg
sot
recipi
cmvseroposit
organ
group
highest
risk
sever
cmv
diseas
hsct
seroposit
recipi
receiv
stem
cell
seroneg
donor
repres
highest
risk
group
cmv
transplant
manifest
clinic
sever
way
fever
alon
cmv
syndrom
fever
evid
myelosuppress
arthralgia
myalgia
invas
diseas
pneumon
enterocol
enceph
hepat
retin
rare
cmv
frequent
detect
month
transplant
lateonset
diseas
increasingli
report
natur
histori
alter
use
antivir
prophylaxi
diagnosi
cmv
dna
plasma
rapidli
detect
quantit
pcr
altern
antigendetect
assay
antigenemia
test
avail
histolog
remain
gold
standard
prove
tissu
invas
diseas
often
necessari
diagnos
coliti
occasion
cmv
dna
undetect
plasma
pcr
cmv
pcr
also
perform
clinic
sampl
site
infect
csf
sever
diseas
best
treat
initi
intraven
ganciclovir
mgkg
everi
hour
initi
oral
valganciclovir
option
patient
mild
symptom
dose
agent
requir
adjust
set
renal
impair
patient
often
requir
reduct
immunosuppress
possibl
cmv
immunoglobulin
cytogam
may
addit
benefit
sever
diseas
particular
cmv
pneumon
recommend
dose
mgkg
time
per
week
treatment
continu
resolut
viremia
ebv
associ
ptld
caus
wide
spectrum
clinic
condit
rang
uncompl
infecti
mononucleosi
true
malign
disord
estim
incid
ptld
sot
recipi
highrisk
hsct
recipi
hla
mismatch
gvhd
tcelldeplet
transplant
attribut
mortal
approach
entiti
often
manifest
nonspecif
febril
ill
approxim
patient
involv
gi
tract
cn
diseas
occas
lead
fulmin
cours
dramat
present
requir
critic
care
support
quantit
ebv
viral
load
test
perform
whole
blood
plasma
csf
indic
radiolog
assessmentstag
requir
positron
emiss
tomographi
ct
scan
brain
mri
adequ
tissu
sampl
histolog
stain
morpholog
situ
hybrid
studi
confirm
diagnosi
mani
differ
modal
use
treatment
reduct
immunosuppress
surgic
excis
local
lesion
eg
gi
tract
mass
ganciclovirvalganciclovir
variabl
efficaci
adopt
immunotherapi
monoclon
antibodi
rituximab
cytotox
chemotherapi
respiratori
syncyti
viru
rsv
parainfluenza
influenza
human
metapneumoviru
adenoviru
enterviru
rhinoviru
coronaviru
common
respiratori
virus
frequent
encount
transplant
recipi
attack
rate
follow
usual
season
pattern
immunocompet
individu
caus
mild
symptom
progress
involv
lower
respiratori
tract
sever
diseas
occur
increas
frequenc
transplant
recipi
pediatr
patient
higher
risk
infect
sever
diseas
diagnosi
specif
virus
detect
direct
fluoresc
antibodi
cultur
multiplex
pcr
nasopharyng
swab
bal
specimen
asid
antivir
therapi
influenza
consensu
exist
treatment
respiratori
virus
earli
treatment
certain
patient
lung
transplant
recipi
hsct
patient
preengraft
use
reduc
risk
lower
tract
diseas
limit
sever
treatment
report
demonstr
efficaci
detail
rsv
aerosol
ribavirin
ae
intraven
immunoglobulin
ivig
palivizumab
antirsv
monoclon
antibodi
also
provid
addit
benefit
ribavirin
parainfluenza
aerosol
ribavirin
ae
ivig
human
metapneumoviru
emerg
respiratori
pathogen
associ
sever
often
fatal
diseas
hsct
recipi
aerosol
ribavirin
ivig
also
use
success
case
report
adenovirida
caus
wide
rang
clinic
syndrom
selflimit
fever
pneumon
hepat
hemorrhag
coliti
rare
adenoviru
caus
sever
dissemin
diseas
multiorgan
failur
manifest
occur
frequent
pediatr
recipi
carri
high
mortal
treatment
option
includ
cidofovir
ribavirin
experiment
drug
aspergillu
spp
aspergillu
common
caus
ifi
allogen
hsct
recipi
incid
sot
recipi
incid
consider
lower
mortal
attribut
invas
aspergillosi
ia
vari
transplant
recipi
although
may
lower
current
era
risk
factor
ia
includ
prolong
neutropenia
lung
transplant
cmv
infect
aspergillu
colon
graft
rejectionfailur
gvhd
iron
overload
lung
sinus
common
site
diseas
involv
patient
present
fever
chest
pain
hemoptysi
dyspnea
pulmonari
diseas
involv
lung
parenchyma
present
diffus
tracheobronch
sinu
diseas
caus
facial
pain
seizur
focal
neurolog
sign
extens
diseas
pulmonari
radiolog
appear
best
appreci
use
ct
includ
nodul
without
cavit
patchi
segment
area
consolid
ground
posttranspl
infect
glass
chang
diseas
outsid
respiratori
tract
occur
cutan
involv
solitari
intracerebr
abscess
sputum
cultur
lack
sensit
isol
aspergillu
alon
reflect
diseas
gold
standard
diagnosi
demonstr
organ
angioinvas
diseas
tissu
biopsi
lung
sinu
tissu
fungal
stain
cultur
specimen
confirm
genu
speci
remain
import
diagnosi
particularli
era
prophylaxi
use
secondgener
triazol
voriconazol
posaconazol
alter
spectrum
speci
encount
galactomannan
constitu
aspergillu
cell
wall
releas
hyphal
growth
estim
galactomannan
serum
wide
use
lack
sensit
test
appear
perform
better
hematolog
patient
sot
recipi
estim
galactomannan
bal
demonstr
superior
sensit
also
perform
csf
specimen
wide
standard
evolut
molecular
assay
use
pcr
add
abil
achiev
definit
diagnosi
voriconazol
accept
treatment
choic
load
dose
mgkg
everi
hour
administ
day
follow
mainten
mgkg
hourli
thereaft
measur
trough
level
advis
approxim
week
therapi
target
rang
mgml
voriconazol
interact
significantli
calcineurin
inhibitor
thu
level
agent
must
also
close
monitor
minimum
week
therapi
advis
durat
guid
clinicoradiolog
resolut
surveil
galactomannan
assay
speci
confirm
vital
guid
therapi
suscept
differ
speci
aspergillu
terreu
aspergillu
calidoustu
vari
consider
novel
antifung
combin
may
requir
surgic
intervent
indic
context
signific
hemoptysi
extens
sinonas
diseas
pathogen
caus
diseas
mimic
ia
repres
consider
emerg
threat
era
posaconazolevoriconazol
prophylaxi
pathogen
note
includ
zygomycet
fusarium
scedosporium
pneumocysti
jirovecci
pneumoniapcp
effect
prophylaxi
dramat
reduc
incid
pneumocysti
jirovecci
pneumonia
pjp
transplant
recipi
howev
remain
pathogen
note
import
diagnost
consider
transplant
patient
present
acut
respiratori
failur
classic
patient
present
subacut
fever
cough
dyspnea
hallmark
pjp
remain
profound
hypoxia
rel
pauciti
clinic
find
chest
radiograph
may
reveal
bihilar
infiltr
pneumothorac
often
quit
unremark
ct
thorax
sensit
diagnosi
diagnosi
best
achiev
via
demonstr
organ
bal
lung
biopsi
specimen
sever
specif
stain
method
use
includ
monofluoresc
antibodi
stain
gomorimethanamin
silver
stain
giemsa
wright
stain
infecti
burden
gener
less
sot
recipi
thu
diagnost
sensit
lower
report
patient
hiv
treatment
trimethoprim
tmp
sulfamethoxazol
remain
treatment
choic
recommend
dose
mgkgd
tmp
compon
divid
dose
advers
effect
frequent
rash
nausea
renal
impair
altern
includ
clindamycin
mg
hourli
primaquin
mg
daili
dapson
mg
daili
tmp
mgkgd
divid
dose
hiv
adjunct
corticosteroid
import
consider
gener
recommend
case
sever
hypoxemia
pao
mm
hg
dose
region
mg
twice
daili
week
follow
taper
week
use
strongyloid
hyperinfect
syndrom
rare
particularli
sever
manifest
latent
strongyloid
infect
primarili
report
sot
recipi
massiv
dissemin
filariform
larva
lung
liver
heart
cn
occur
concomit
gramneg
bsi
bacteri
mening
recogn
patient
present
sever
system
ill
mortal
high
diagnosi
achiev
via
detect
larva
stool
respiratori
secret
csf
treatment
ivermectin
mgkgd
albendazol
mg
twice
daili
extend
cours
advis
set
hyperinfect
transplant
recipi
transplant
recipi
repres
complex
heterogen
patient
popul
often
requir
period
critic
care
support
infecti
complic
precipit
major
admiss
critic
care
posttransplant
patient
suscept
increasingli
divers
array
common
opportunist
infect
pathogen
clinician
must
maintain
high
index
suspicion
infect
conduct
earli
thorough
diagnost
workup
coupl
prompt
institut
antimicrobi
therapi
detail
individu
infect
risk
assess
central
guid
therapeut
care
pathway
optim
clinic
outcom
